Oncolytics Biotech (ONCY)
(Delayed Data from NSDQ)
$0.93 USD
-0.03 (-2.99%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $0.94 +0.01 (1.08%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth C Momentum F VGM
Income Statements
Fiscal Year end for Oncolytics Biotech Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 25 | 21 | 21 | 19 | 16 |
Income After Depreciation & Amortization | -25 | -21 | -21 | -19 | -16 |
Non-Operating Income | 5 | 2 | 0 | 2 | -9 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -20 | -19 | -21 | -17 | -25 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -21 | -19 | -21 | -17 | -25 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -21 | -19 | -21 | -17 | -25 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -25 | -20 | -21 | -19 | -15 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -25 | -21 | -21 | -19 | -16 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 67.62 | 58.03 | 53.51 | 40.34 | 22.14 |
Diluted EPS Before Non-Recurring Items | -0.30 | -0.33 | -0.39 | -0.53 | -0.70 |
Diluted Net EPS (GAAP) | -0.30 | -0.33 | -0.39 | -0.42 | -1.13 |
Fiscal Year end for Oncolytics Biotech Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 5.79 | 6.47 | 6.50 | 8.23 | 5.32 |
Income After SG&A, R&D, and Dept/Amort Expenses | -5.79 | -6.47 | -6.50 | -8.23 | -5.32 |
Non-Operating Income | 0.55 | 1.36 | 3.66 | 0.84 | -0.17 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -5.23 | -5.11 | -2.84 | -7.39 | -5.50 |
Income Taxes | 0.07 | 0.00 | 0.03 | 0.01 | 0.03 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -5.30 | -5.11 | -2.87 | -7.40 | -5.53 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -5.30 | -5.11 | -2.87 | -7.40 | -5.53 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 76.09 | 75.25 | 78.00 | 69.80 | 64.47 |
Diluted EPS Before Non-Recurring Items | -0.07 | -0.07 | -0.04 | -0.10 | -0.09 |
Diluted Net EPS (GAAP) | -0.07 | -0.07 | -0.03 | -0.11 | -0.09 |